These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31800986)

  • 21. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono A; Nébié I; Konaté A; Berges GD; Diarra A; Ouedraogo M; Bougouma EC; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Oshinsky JJ; Pasetti MF; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jul; 108():465-472. PubMed ID: 34082090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries.
    Shakya M; Neuzil KM; Pollard AJ
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S770-S774. PubMed ID: 34374785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
    Choi SK; Baik YO; Kim CW; Kim SK; Oh IN; Yoon H; Yu D; Lee C
    Vaccine; 2021 May; 39(19):2620-2627. PubMed ID: 33849723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
    Chaudhary S; Shah GS; Bhatta NK; Poudel P; Rai B; Uranw S; Tripathi PM; Khanal B; Ghimire A; Rai N; Gupta BP; Vemula S; Wartel TA; Sahastrabuddhe S; Saluja T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2203634. PubMed ID: 37128723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
    Thobani RS; Yousafzai MT; Sultana S; Kazi AM; Jan M; Rafey A; Khan A; Irfan S; Ujjan IU; Brown N; Mårtensson A; Qamar FN
    Vaccine; 2022 Aug; 40(36):5391-5398. PubMed ID: 35945044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
    Saluja T; Rai GK; Chaudhary S; Kanodia P; Giri BR; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Vaccine; 2022 Sep; 40(40):5828-5834. PubMed ID: 36064672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
    Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
    BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas.
    Birkhold M; Mwisongo A; Pollard AJ; Neuzil KM
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S781-S787. PubMed ID: 34528085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data.
    Liang Y; Driscoll AJ; Patel PD; Datta S; Voysey M; French N; Jamka LP; Henrion MYR; Ndeketa L; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM
    Lancet Glob Health; 2023 Jan; 11(1):e136-e144. PubMed ID: 36442498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.
    Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
    Int J Infect Dis; 2020 Apr; 93():102-107. PubMed ID: 32004693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM
    Thuluva S; Paradkar V; Matur R; Turaga K; Gv SR
    Hum Vaccin Immunother; 2022 Nov; 18(5):2043103. PubMed ID: 35333702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children.
    Vadrevu KM; Dugyala R; Mahantashetti NS; Khalatkar V; Murthy K; Mogre S; Mitra M
    Hum Vaccin Immunother; 2022 Dec; 18(7):2150030. PubMed ID: 36476258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
    Capeding MR; Alberto E; Sil A; Saluja T; Teshome S; Kim DR; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ham DS; Ryu JH; Lynch J; Kim JH; Kim H; Excler JL; Wartel TA; Sahastrabuddhe S
    Vaccine; 2020 Jun; 38(28):4476-4483. PubMed ID: 31585725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.